Iqvia (NYSE:IQV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, February 20th.
According to Zacks, “IQVIA Holdings Inc. is a provider of information, innovative technology solutions and contract research services focused on using data and science which offer healthcare clients find better solutions for their patients. IQVIA Holdings Inc., formerly known as Quintiles IMS Holdings, Inc., is based in DURHAM, United States. “
A number of other equities research analysts have also issued reports on the stock. TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Stifel Nicolaus raised shares of Iqvia from a “hold” rating to a “buy” rating and raised their target price for the company from $92.00 to $128.00 in a report on Friday, October 27th. Royal Bank of Canada set a $118.00 target price on shares of Iqvia and gave the company a “buy” rating in a report on Thursday, February 15th. Jefferies Group raised their price target on Iqvia from $107.00 to $110.00 and gave the stock a “hold” rating in a research report on Monday, October 30th. Finally, SunTrust Banks restated a “hold” rating and issued a $114.00 price target on shares of Iqvia in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $110.02.
Iqvia (IQV) traded down $0.84 on Tuesday, reaching $104.84. 1,111,427 shares of the company’s stock traded hands, compared to its average volume of 1,186,370. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. The company has a market cap of $22,062.05, a PE ratio of 17.33, a P/E/G ratio of 2.71 and a beta of 0.64. Iqvia has a 1-year low of $76.80 and a 1-year high of $110.67.
Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the company earned $1.09 EPS. research analysts forecast that Iqvia will post 2.84 earnings per share for the current fiscal year.
In other news, Director Michael J. Evanisko sold 816 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $101.21, for a total value of $1,012,100.00. The disclosure for this sale can be found here. Insiders sold 30,816 shares of company stock valued at $3,093,400 over the last three months. 6.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Iqvia during the fourth quarter worth approximately $942,532,000. Longview Partners Guernsey LTD purchased a new stake in Iqvia in the 4th quarter valued at $927,548,000. Jackson Square Partners LLC purchased a new stake in Iqvia in the 4th quarter valued at $464,053,000. Farallon Capital Management LLC purchased a new stake in Iqvia in the 4th quarter valued at $290,072,000. Finally, Alliancebernstein L.P. purchased a new stake in Iqvia in the 4th quarter valued at $253,128,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2018/03/14/zacks-investment-research-lowers-iqvia-iqv-to-sell.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.